Jump to main content
Jump to site search


Ferumoxytol of ultrahigh magnetization produced by hydrocooling and magnetically internal heating co-precipitation

Author affiliations

Abstract

Ferumoxytol, which is originally intended for MRI and anemia treatment, is currently the only inorganic nanodrug approved by FDA for clinical application in vivo. Common ferumoxytol seems incapable of meeting the requirements for diverse applications. Thus, the development of a novel strategy based on co-precipitation to produce ferumoxytol with high quality is an imminent task. Herein, we proposed a physically assisted strategy, namely hydrocooling and magnetically internal heating co-precipitation, to optimize the properties of ferumoxytol and thus significantly enhance its magnetic performance. Magnetization of the newly developed ferumoxytol can reach 104ā€“105 emu gāˆ’1 Fe, which is the highest value among the reported results. It has been found that the crystalline structures of the newly developed ferumoxytol have been greatly improved on the basis of pharmaceutical quality criteria.

Graphical abstract: Ferumoxytol of ultrahigh magnetization produced by hydrocooling and magnetically internal heating co-precipitation

Back to tab navigation

Supplementary files

Publication details

The article was received on 26 Jan 2018, accepted on 22 Mar 2018 and first published on 29 Mar 2018


Article type: Communication
DOI: 10.1039/C8NR00736E
Citation: Nanoscale, 2018, Advance Article
  •   Request permissions

    Ferumoxytol of ultrahigh magnetization produced by hydrocooling and magnetically internal heating co-precipitation

    B. Chen, J. Sun, F. Fan, X. Zhang, Z. Qin, P. Wang, Y. Li, X. Zhang, F. Liu, Y. Liu, M. Ji and N. Gu, Nanoscale, 2018, Advance Article , DOI: 10.1039/C8NR00736E

Search articles by author

Spotlight

Advertisements